A second pivotal trial of imeglimin in patients with type 2 diabetes mellitus

Trial Profile

A second pivotal trial of imeglimin in patients with type 2 diabetes mellitus

Planning
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Imeglimin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 31 Oct 2017 New trial record
    • 30 Oct 2017 According to a Sumitomo Dainippon Pharma media release, this trial is a part of the phase III program in Japan that includes 3 pivotal studies with approximately 1100 patients that will support regulatory submissions to the Pharmaceuticals and Medical Devices Agency (PMDA). This trial is expected to be initiated by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top